Projecting future drug expenditures - 1996

American Journal of Health-System Pharmacy

Volumn 53, Issue 2, 1996, Pages 139-150

  Santell, John P ^a  

^a AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS   (United States)

Author keywords

Administration; Budgets; Costs; Drug use; Drugs; Economics; Legislation; Managed care systems; Pharmacoeconomics; Pharmacy, institutional

Indexed keywords

GENERIC DRUG; NEW DRUG;

DRUG COST; DRUG INDICATION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG USE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE DELIVERY; HUMAN; MEDICAID; MEDICARE; PATENT; PHARMACIST; PHARMACOECONOMICS; PRIORITY JOURNAL; REVIEW;

EID: 0030042550     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.2.139     Document Type: Review

References (21)

1. Burner ST, Waldo DR. National health expenditure projections, 1994-2005. Health Care Financ Rev. 1995; 16(4):221-42.
2. Johnson, JA, Bootman JL. Drug-related morbidity and mortality. Arch Intern Med. 1995; 155:1949-56.
3. Riccardo JP, Shevick SJ. Pharmaceutical industry equity research. Phase ix: mix and fix. New York: Bear, Stearns; 1995.
4. Santell JP. Projecting future drug expenditures - 1995. Am J Health-Syst Pharm. 1995; 52:151-63.
5. Santell JP. Projecting future drug expenditures - 1994. Am J Hosp Pharm. 1994; 51:177-87.
6. Santell JP. Projecting future drug expenditures - 1993. Am J Hosp Pharm. 1993; 50:71-7.
7. Ensor PA. Projecting future drug expenditures - 1992. Am J Hosp Pharm. 1992; 49:140-5.
8. Bureau of Labor Statistics. Summary data from the producer price index: 1991-1995. Washington, DC: U.S. Department of Labor; 1995.
9. Tanouye E. Big drug makers regaining control over their prices. Wall St J. 1995; Jul 12:B4.
10. Kassirer JP, Angell M. The Journal's policy on cost-effectiveness analyses. N Engl J Med. 1994; 331:669-70.
11. Evans RG. Manufacturing consensus, marketing truth: guidelines for economic evaluation. Ann Intern Med. 1995; 123:59-60. Letter.
12. Langley PC. Comment: substantiation in pharmacoeconomic evaluations. Ann Pharmacother. 1995; 29:942-3.
13. Udvarhelyi IS, Colditz GA, Rai A et al. Adherence to analytic principles among 77 pharmacoeconomic articles reviewed. Ann Intern Med. 1992; 116:238-44.
14. Outcomes of Pharmaceutical Therapy (OPT) Program update. July, 1995. Rockville, MD: Agency for Health Care Policy and Research; 1995.
15. Ries AJ, Potyk RP, Brier KL et al. The military health services system model for pharmacoeconomic decision making. Med Interface. 1995; 8(May): 132-7.
16. Schondelmeyer S. Economic impact of GATT patent extension. Minneapolis: PRIME Institute; 1995.
17. New drug approvals in 1994. 1995 survey report. Washington, DC: Pharmaceutical Research and Manufacturers of America; 1995.
18. Biotechnology medicines in development. 1995 survey report. Washington, DC: Pharmaceutical Research and Manufacturers of America; 1995.
19. Gouveia WA. The rising cost of pharmaceuticals: understanding and managing the escalating cost of pharmaceuticals in health care institutions. Am J Hosp Pharm. 1993; 50(Suppl 4):S1-18.
20. Mehl B. 1993 changes in drug cost for inpatient services. Hasp Pharm. 1994; 29:771-3.
21. Mehl B. Indicators to control drug costs in hospitals. Am J Hosp Pharm. 1984; 41:667-75.